title: Chronic angiotensin converting enzyme inhibition enhances renal vascular responsiveness to acetylcholine in anaesthetized rabbits.
abstract: OBJECTIVE
  To determine whether 6 weeks continuous treatment with an angiotensin converting enzyme (ACE) inhibitor reduced renal vascular responsiveness in vivo, since this treatment results in extensive phenotypic conversion of afferent arteriolar cells from contractile to endocrine-like, renin secretory cells.
  
  
  METHODS
  Enalapril (10 microg/kg per h s.c.) was delivered continuously for 6 weeks. In anaesthetized rabbits (treated or sham), arterial blood pressure and renal blood flow were measured and renal responsiveness tested by constructing dose-response curves to bolus doses of phenylephrine, angiotensin II and acetylcholine delivered directly into the renal artery.
  
  
  RESULTS
  ACE inhibition resulted in a significant shift to the left in the renal vascular conductance responses to acetylcholine (P < 0.005) and angiotensin II (P < 0.05), indicating enhanced, not reduced, responsiveness to these agents. There were no significant effects of chronic ACE inhibition on the conductance responses to phenylephrine.
  
  
  CONCLUSIONS
  Contrary to our hypothesis, 6 weeks ACE inhibition did not reduce renal vascular responsiveness to three vasoactive agents, suggesting that the phenotypic changes observed in the afferent arterioles and to a lesser extent the interlobular arteries, were either insignificant or compensated for by other changes in renal circulatory control.
authors.affiliation: Department of Physiology, Monash University, Clayton, VIC, Australia. k.denton@med.monash.edu.au
authors.forename: K M
authors.initials: KM
authors.lastname: Denton
authors.forename: M
authors.initials: M
authors.lastname: Lamden
authors.forename: A
authors.initials: A
authors.lastname: Shweta
authors.forename: D
authors.initials: D
authors.lastname: Alcorn
authors.forename: W P
authors.initials: WP
authors.lastname: Anderson
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology*; D000804:Angiotensin II / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001160:Arterioles / Q000187:drug effects / Q000473:pathology; D004656:Enalapril / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D011817:Rabbits; D012077:Renal Artery / Q000187:drug effects / Q000473:pathology; D012079:Renal Circulation / Q000187:drug effects*; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000804:Angiotensin II; D004656:Enalapril; D000109:Acetylcholine